Company Profile
Exact Sciences Stock Price, News & Analysis
- Ticker:
- EXAS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for EXAS.
Company overview
Business overview
Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology testing. Its most visible franchise is in colorectal cancer screening, but the broader business is built around non-invasive diagnostics and oncology-related testing.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Exact Sciences sits in diagnostics and molecular testing. It is a healthcare innovation company rather than a therapeutic biotech.
Business Model Characteristics
The company earns revenue from diagnostic test adoption, lab workflows, and cancer-screening expansion. Investors watch test volume, reimbursement, product rollout, and the potential for additional oncology diagnostics to broaden the franchise.
Position Within the Biotechnology Landscape
Exact Sciences sits near the diagnostics edge of the biotech landscape. It is less binary than a drug developer but still sensitive to adoption trends, reimbursement, and product performance.
Future catalysts
Exact Sciences’ catalysts are Cologuard Plus progress, screening utilization, and any regulatory or commercial update that broadens the early-detection franchise. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Exact Sciences do?
Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology testing. Its most visible franchise is in colorectal cancer screening, but the broader business is built around non-invasive diagnostics and oncology-related testing.
On which exchange is EXAS stock listed?
Exact Sciences (EXAS) is associated with NASDAQ, United States, Biopharma.
What is Exact?
Exact Sciences’ catalysts are Cologuard Plus progress, screening utilization, and any regulatory or commercial update that broadens the early-detection franchise.
Which conditions is Exact Sciences targeting with Exact?
Exact Sciences is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Exact Sciences describe recent progress with Exact?
Exact Sciences’ catalysts are Cologuard Plus progress, screening utilization, and any regulatory or commercial update that broadens the early-detection franchise.
What is Sciences?
Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology testing.
What should investors watch for with Sciences?
Exact Sciences’ catalysts are Cologuard Plus progress, screening utilization, and any regulatory or commercial update that broadens the early-detection franchise.
What is Cologuard?
Exact Sciences’ catalysts are Cologuard Plus progress, screening utilization, and any regulatory or commercial update that broadens the early-detection franchise.